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Abstract
Introduction Health economic models are increasingly
important in funding decisions but most are based on data,
which may therefore not represent the general population.
We sought to establish the potential of real-world data
available within the Clinical Practice Research Datalink
(CPRD) and linked Hospital Episode Statistics (HES) to
determine comprehensive healthcare utilisation and costs
as input variables for economic modelling.
Methods A cohort of patients with irritable bowel syn-
drome (IBS) who first saw a gastroenterologist in 2008 or
2009, and with 3 years of data before and after their
appointment, was created in the CPRD. Primary care,
outpatient, inpatient, prescription and colonoscopy data
were extracted from the linked CPRD and HES. The
appropriate cost to the NHS was attached to each event.
Total and stratified annual healthcare utilisation rates and
costs were calculated before and after the gastroenterology
appointment with distribution parameters. Absolute dif-
ferences were calculated with 95 % confidence intervals.
Results Total annual healthcare costs over 3 years
increase by £935 (95 % CI £928–941) following a gas-
troenterology appointment for IBS. We derived utilisation
and cost data with parameter distributions stratified by
demographics and time. Women, older patients, smokers
and patients with greater comorbidity utilised more
healthcare resources, which generated higher costs.
Conclusions These linked datasets provide comprehen-
sive primary and secondary care data for large numbers of
patients, which allows stratification of outcomes. It is
possible to derive input parameters appropriate for eco-
nomic models and their distributions directly from the
population of interest.
Key Points for Decision Makers
Accurate costs from the health service perspective
can be precisely attached to the Clinical Practice
Research Datalink (CPRD) and linked Hospital
Episode Statistics (HES) data at an individual level,
and these data can be used to calculate accurate total
healthcare utilisation rates and costs.
There are sufficient data available to allow multiple
stratification that reflects patient heterogeneity.
The outcomes generated from these methods at
either an individual or cohort level can be used
directly as input parameters for further economic
modelling, which will enhance healthcare policy and
decision making.
1 Introduction
Health economic evaluations are becoming increasingly
important in the decisions made regarding healthcare pro-
vision and policy. In many healthcare settings, funding for
a service, drug or intervention is dependent on
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demonstrating its cost effectiveness. These evaluations
require complete and detailed longitudinal data for large
numbers of patients regarding the course of their health
conditions, the consequences and the costs [1]. Histori-
cally, this has been difficult to retrieve or compile. The
increase in electronic collection of routine healthcare data
means real-world data are becoming more available. Real-
world evidence from electronic health records represents
actual clinical practice and patient heterogeneity in a way
not often reflected within randomised controlled trials
(RCTs) [2, 3]. The large number of patients available for
study provides the opportunity for subgroup stratification
and assessment of rare diseases and outcomes, which is
usually not possible with RCT data. An additional benefit is
the many years of data available for each patient [2].
Until recently, datasets have allowed analysis of only
one aspect of patient care. These have included care from a
single provider, only primary care, only inpatient or out-
patient hospital care, or mortality. Recent developments in
data linkage now allow analysis of the majority of
healthcare accessed by patients in England across domains
paid for by the National Health Service (NHS) [4, 5].
Detailed data for calculating healthcare cost according to
the UK NHS payment and reimbursement system are also
publically available [6, 7]. Combining these data offers
new potential to assess complete utilisation and cost of
healthcare from the perspective of the UK NHS as payer.
This study assesses the feasibility of using linked elec-
tronic health records to calculate the cost of healthcare
utilisation across primary and secondary healthcare settings.
In the UK, all secondary care is provided within a hospital
setting. Our aimwas to generate stratified utilisation and cost
data that could be suitable input parameters for future eco-
nomic modelling. To do this, we set out to answer the
question ‘‘What is the effect on the pattern and cost of
healthcare utilisation of a referral to see a gastroenterologist
among people with irritable bowel syndrome (IBS)?’’.
IBS is a chronic, nonfatal condition, diagnosed in 11 %
of the population [8]. Patients experience abdominal pain
with diarrhoea or constipation, or both, but they have no
structural bowel abnormality. International guidelines rec-
ommend diagnosis of IBS according to clinical criteria
within primary care with minimal investigation, and also
recommend IBS management within primary care [9–12].
Despite this, up to 20 % of patients are referred to see a
gastroenterologist [13], and managing IBS constitutes
between 25 and 50 % of gastroenterology outpatient
workload [14–17]. Our study used linked electronic
healthcare data from primary and secondary care in Eng-
land to calculate rates and costs of healthcare utilisation for
patients with IBS before and after their first appointment
with a gastroenterologist.
2 Methods
2.1 Data Source
The Clinical Practice Research Datalink (CPRD) is an
anonymised longitudinal dataset of over 13 million medi-
cal records from over 640 primary care practices across the
UK, collected prospectively from routine care since 1987
[4, 18]. It contains details of all primary care contact a
person has had, the reason for the contact, who it was with
and any medication prescribed. Records of almost two-
thirds of English practices within the CPRD are linked to
the NHS Hospital Episode Statistics (HES) [4, 5], which
provide secondary care inpatient data from NHS hospitals
in England since 1989 and outpatient data from 2004.
The cost to the health service of primary care utilisation is
calculated nationally from unit costs, and is reported, along
with social care costs, as NHS reference costs [6]. Costs of
medication prescribed in primary care are contained in the
British National Formulary (BNF). In England, the cost of
secondary care to the health service (the payer) is calculated
according to national tariff prices, based on the national
average unit costs of providing each service (published as
the National Schedule of Reference Costs [19]). The cur-
rency of patient activity used to attract a tariff is the
Healthcare Resource Group (HRG) [7]. This is calculated
according to an algorithm that clusters diagnostic codes,
treatments and procedures with similar resource implica-
tions [7]. To generate the appropriate HRG code, secondary
care events are grouped into spells, which include the dif-
ferent diagnoses made, the events that occurred during an
admission, such as different specialists involved in care,
procedures and investigations (not including blood tests),
and the duration of care in different settings. The algorithm
provides a hierarchy of the events coded within each spell,
with adjustment for market factor forces and patient demo-
graphics, all of which are contained within the HES data.
The National Casemix Office generates this algorithm and
grouping software in order to attach the HRG data to the
HES data [7]. The HRGs are currently updated annually in
line with the tariff. Consequently, like the tariff, HRGs are
year-specific. This study uses one cohort to compare costs
before and after an intervention. To ensure changes in cost
were from changes in utilisation and not changes within the
HRG algorithm or tariff rates, the same HRG grouping
algorithm was used for data in all years. We used 2012/2013
HRGs and tariff as they were the most recent and most
consistent with the latest data we had available. For con-
sistency, we used the 2012 unit and reference costs.
Where tariff costs do not exist, usually for rare condi-
tions or treatments, reference costs are generated from the
national average of the unit cost of care [19].
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2.2 Irritable Bowel Syndrome (IBS) Cohort
Construction of the initial cohort of patients with IBS has
been fully described previously [20]. Briefly, individuals
with records audited to acceptable research quality (where
the record is checked for concordant dates, demographic
data and consistent registration [18]) from CPRD practices
with HES-linked data were identified as having IBS if they
had a diagnostic (Read) code for IBS in either their CPRD
clinical or referral file. The first event within the patient
record explicitly coded as IBS defined the date of diag-
nosis. Patients were excluded if they had any diagnostic
code for inflammatory bowel disease, colorectal cancer or
coeliac disease recorded within their entire health record.
Patients have one unique HES identifier for all their sec-
ondary care records across the UK. If a patient moves
between CPRD primary care practices they receive a new
identifier and their records within the CPRD are not linked.
Multiple CPRD records with one HES identifier were
excluded (Fig. 1).
The first gastroenterology appointment was defined as a
patient’s earliest recorded gastroenterology appointment
within the HES outpatient data. The HES outpatient data
are only available to link to CPRD records from 2004. Our
datasets contained data until the end of 2012. To allow 3
full years of data for all healthcare domains before and
after gastroenterology appointment, we selected those
patients who had their first gastroenterology appointment
in 2008 or 2009. Patients with fewer than 3 full years of
data before or after the gastroenterology appointment were
excluded.
2.3 Primary Care
Each primary care attendance was identified within the
CPRD clinical file along with the professional with whom
Fig. 1 Process depicting how the cohort of patients with IBS referred to gastroenterology in 2008 or 2009 was constructed within the CPRD. IBS
irritable bowel syndrome, CPRD Clinical Practice Research Datalink
Calculating Total Health Service Utilisation and Costs
the consultation occurred. Appropriate reference costs were
attached from the unit costs of health and social care [6].
Where consultation type was unknown (8.5 % of all con-
sultations across the entire study period), a weighted
average of the costs of the different consultation types
available was used. This was calculated by summing the
product of the proportion of each consultation type and its
cost in each year.
2.4 Prescriptions
For each subject, we identified every separate prescription
recorded in the CRPD prescriptions file. Drugs were clas-
sified according to their BNF chapter subparagraph, and the
mean subparagraph cost was attached according to the
2012 England Prescription Cost Analysis (Health and
Social Care Information Centre) [21]. Where missing data
for the specific drug supplied prevented this (0.04 % of
prescriptions), we attributed the 2012 median prescription
cost as reported in the Prescription Cost Analysis (£38.74)
[21].
2.5 Secondary Care
HES outpatient data were used to identify each attendance
and specialty. Costs were taken from the NHS 2012 tariff
for outpatient care. Costs in the tariff differ if appointments
are first or subsequent visits, which are coded in HES so
appropriate costs were attributed. Within HES, the treat-
ment function code represents the specialised service
within which a patient is treated [7, 22]. Events were linked
to cost through the treatment function code within the HES
outpatient data. All attendances were considered as single-
consultant appointments for costing purposes, not multi-
disciplinary team appointments. Outpatient appointments
excluded from Payment by Results (the tariff system that
reimburses healthcare providers in the NHS [23]) in 2012,
or occurring too infrequently at a national level, were not
covered by the 2012 tariff. Costs for these appointments
were taken from the unit price reported by appointment
type in the 2012 reference costs [19].
Hospital admissions, including both day case and inpa-
tient spells, but excluding colonoscopy, were extracted
from HES data. Each separate hospital spell was identified
for each patient along with the main treatment specialty.
Spells with day-case codes, or inpatient stays of 1-day
duration, were considered as day-case admissions. The
HES inpatient data were reformatted so that the NHS 2012
grouper could be used to generate the appropriate HRG for
each spell using the hierarchical algorithm [7]. These
HRGs were linked to the 2012 NHS tariff costs. Elective or
emergency prices were attached as appropriate and, if this
status was unknown, elective prices were used. HRGs with
no national tariff were identified and the appropriate price
for each admission was attached from the 2012 reference
costs [19]. The mean cost of day-case attendance in 2012
was £682, and £3215 per stay for inpatient admission; these
costs were used when no reference costs were available.
2.6 Colonoscopy
Individual procedures can be specifically isolated and the
cost attached. We identified colonoscopies in both the HES
outpatient and hospital admissions data, and classified each
procedure as elective or emergency according to coding in
the dataset. The 2012 NHS tariff costs were attached.
2.7 Analysis
The duration of IBS before referral was defined as the time
from the first IBS code in the patient record. Socioeco-
nomic status within the CPRD dataset is on a patient
postcode level [4] and is defined according to the quintile
of the index of multiple deprivation. Smoking status was
defined as ever or never smokers. The full clinical data
available within the CPRD and HES record until 31
December 2012 were used to identify comorbidities, and
from these the Charlson index was calculated [24]. For
analysis, patients were classified as having no comorbidi-
ties (a score of 0) or comorbidities (a score of 1 or greater).
Poisson regression analysis was used to generate adjusted
rate ratios (RR), with robust standard errors used to pro-
duce 95 % confidence intervals (CI) for each of the
domains of healthcare utilisation over the entire 6 years of
data according to demographic strata. Three 1-year bands
were defined for each patient before and after the date of
the gastroenterology appointment, and the mean annual
utilisation rates and costs were calculated. Rates of utili-
sation were approximately normally distributed and are
presented in summary as mean and 95 % CI. Absolute
differences in utilisation rate were calculated in each
domain compared with the rate in the year 3 years before
the gastroenterology appointment, and are presented with
95 % CIs. We hypothesised a priori that the use of
healthcare might increase, leading to a referral to see a
gastroenterologist for IBS, and fall afterwards. Conse-
quently, we took 3 years before referral as the baseline year
with which to compare utilisation rates. Absolute differ-
ences were reported as these were the most useful data for
economic analyses. Mean individual annual costs by
domain were calculated. The cost data best fit gamma
distributions, therefore alpha and lambda parameters were
calculated. The absolute cost difference and 95 % CI was
calculated for total individual annual costs compared with
the baseline year. Stratified overall annual mean costs and
gamma distribution parameters were calculated according
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to sex, age at referral, duration of IBS, socioeconomic
status, smoking status and comorbidity status. No costs
were discounted. All analyses were conducted using Stata
version 12 (StataCorp LP, College Station, TX, USA) [25].
3 Results
Our original cohort identified 256,060 patient records that
had been audited as acceptable for research from HES-
linked CPRD practices, with IBS Read codes in either the
clinical or referral file [20]. No HES outpatient data were
available for 13 % of cases. Linking the HES data to the
CPRD records identified 4562 patients (2 %) with multiple
CPRD identities. Duplicated records or inconsistent dates
were found in 12 % of the HES outpatient records, and
these patient records were entirely excluded as it was not
possible to establish which data were accurate. Of the IBS
patients identified, 11 % had a gastroenterology outpatient
appointment between 2004 and 2012. Of these, 4809 had a
first gastroenterology outpatient appointment in 2008 or
2009. Three full years of CPRD and HES data before and
after the gastroenterology appointment were available for
2076 of these patients (Fig. 1). Table 1 shows the demo-
graphic data for this cohort. The median duration of IBS
before a first gastroenterology outpatient appointment was
4.9 years (interquartile range [IQR] 0.2–12.4 years), 72 %
(1520) were female, and the patients’ mean age at their
gastroenterology appointment was 51.8 years (95 % CI
51.2–52.5 years).
3.1 Healthcare Utilisation
Increasing age and having IBS for longer than 2 years
before referral to gastroenterology were both associated
with increased primary care attendance, prescriptions and
outpatient appointments (Table 2). Women utilised 26 %
more primary care services, 21 % more outpatient services
and had 35 % more prescriptions relative to men. There
was no statistically significant difference in the rates of
colonoscopies or inpatient admissions according to sex or
age at referral. Rates of utilisation in all domains of
healthcare, with the exception of colonoscopy, increased
with improved deprivation. Rates of colonoscopy were
almost double in nonsmokers, while rates of utilisation in
all other healthcare domains were 7–40 % higher in
smokers. The presence of comorbid conditions increased
patients’ healthcare utilisation in all domains, with the
exception of colonoscopy, by approximately 20 %
(Table 2).
Over time, primary care utilisation, hospital inpatient,
day-case admissions, outpatient appointments and colono-
scopy rates all showed a similar pattern of utilisation,
increasing before referral and peaking around the first
gastroenterology appointment. The rates subsequently fell,
but remained higher than pre-referral level (Table 3).
Prescriptions have substantially higher rates in the years
following referral compared with the years before referral.
When considering the absolute difference, compared with
3 years before referral, there were 15 extra prescriptions
per person per year (increased from 26 to 41) 3 years after
referral. For every two patients, there were three extra
primary care and three extra outpatient appointments.
3.2 Costs
Overall healthcare costs per patient increased by less than
25 % in the 3 years leading up to the first gastroenterology
appointment (total mean individual cost increased by £772
(95 % CI £769–776) (Table 4). In the first year following,
overall costs were £1393 higher than at baseline (95 % CI
£1389–1396) and £625 higher than the year before gas-
troenterology appointment. After 3 years following referral,
total costs per person remained one-third higher than they
were 3 years before referral, i.e. £3567 compared with
£2323, an increase of £1244 (95 % CI £1240–1248). Fig-
ure 2 shows the proportion of these costs each year that
corresponded to each domain. Prescriptions accounted for
over half of the total cost each year. Tables 5 and 6 show the
stratified costs with gamma distribution parameters. The
stratified data show similar patterns in costs as the RRs
earlier described.
4 Discussion
This study demonstrates that the linked CPRD and HES
data can be used to measure rates and change in healthcare
utilisation with precise costs for patients. Using linked data
of this type will potentially improve the validity of eco-
nomic models considering complex healthcare interven-
tions in real populations. Absolute difference in annual
utilisation is important to measure for most economic
evaluations. We have been able to use these data to cal-
culate the difference in rates of inpatient, outpatient, and
primary care and prescriptions before and after an inter-
vention. Similarly, we have been able to attach the exact
cost for each patient’s specific care use across the domains
of healthcare for which the NHS is the payer. The data
available within these datasets allowed the generation of
stratified outcomes, useful for scenario analyses. We have
reported costs with the appropriate distribution parameter
values, suitable to input into economic modelling. Gener-
ating these parameters directly from the data without
requiring any assumptions provides realistic parameters for
probabilistic sensitivity analyses.
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4.1 Previous Studies
The CPRD (known as the General Practice Research
Database until 2012 [26]) and linked HES are well-estab-
lished data sources for epidemiological and pharmacovig-
ilance studies [27, 28]. Primary care data from the CPRD
were first used as part of a cost-burden study 25 years ago
[29], before reimbursement using HRGs was introduced
(2003) and before HES-linked data were available (2008).
In addition, before this linkage was available, but since
costs have been calculated using HRGs, a series of studies
comparing the comparative effectiveness and costs of
various treatments for glaucoma were conducted [30–33].
These studies extracted utilisation data from the CPRD, but
without HES linkage they used data within the CPRD
referral file as evidence of secondary care attendance. This
method has continued to be used following the linkage
[34–39], but it misses events and the timing of events is
less accurate than using HES data [40]. Our study was the
first to use HES data to directly assess inpatient and out-
patient secondary care use linked to the CPRD as the
source of primary care use. Unit costs have been used in
previous studies in place of calculating HRGs [30–36, 41].
The unit costs provide the national average cost of each
type of care episode, whilst the HRG gives the specific cost
generated by that patient for that event. Consequently, the
Table 1 Demographics for all patients within the CPRD with IBS and appropriate HES data available for analysis; those referred to gas-
troenterology for the first time in 2008 or 2009; and those patients with 3 full years of data available before and after referral
All IBS cases defined
within the CPRD with
available and reliable
HES data (see Fig. 1)
All IBS patients in the
CPRD referred to
gastroenterology
in 2008 or 2009
IBS patients in the CPRD
referred to gastroenterology
in 2008 or 2009 with 3 years
of data either side of
the appointment
Total number of IBS patients in the cohort 191,788 4809 2076
Sex
Male 48,840 (25) 1335 (27.8) 556 (26.8)
Female 142,948 (75) 3474 (72.2) 1520 (73.2)
Age at gastroenterology outpatient appointment, years
Mean (95 % CI) NAa 50.2 (49.7–50.6) 51.8 (51.2–52.5)
18–29 – 669 (14) 195 (9)
30–49 – 1729 (36) 748 (36)
50–75 – 2411 (50) 1133 (55)
Years from IBS diagnosis to referral
Median (IQR) NAa 4.4 (0.1–12.1) 4.9 (0.2–12.4)
IBS diagnosis at or following GI appointment – 1086 (23) 450 (22)
Within first year – 645 (13) 257 (12)
1–2 – 256 (5) 107 (5)
2–5 – 527 (11) 222 (11)
5–10 – 815 (17) 358 (17)
More than 10 – 1480 (31) 682 (33)
SES: quintile according to Index of Multiple Deprivation
1 (least) 47,330 (25) 1194 (25) 569 (28)
2 44,946 (24) 1107 (23) 462 (22)
3 37,871 (20) 899 (19) 386 (19)
4 33,998 (18) 877 (18) 344 (17)
5 (most) 26,156 (14) 706 (15) 302 (15)
Smoking
Smokers 43,152 (23) 1087 (23) 501 (24)
Comorbidities
Charlson score of 1 or greater 44,111 (23) 1195 (25) 527 (25)
Data are expressed as n (%) unless otherwise specified
CPRD Clinical Practice Research Datalink, IBS irritable bowel syndrome, HES Hospital Episode Statistics, NA not applicable, CI confidence
interval, IQR interquartile range, GI gastrointestinal
a Only 11 % of these patients have a referral, therefore these variables are not relevant
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HRGs provide a far more precise cost estimate, but patient-
specific HRGs cannot be calculated in the absence of the
HES data.
4.2 Strengths of These Linked Datasets
The large number of patient records contained within these
datasets is a great strength. It allows both greater precision
of utilisation and cost estimates and stratification by many
variables with adequate power. Within this study, it has
meant that we have been able to demand a number of
eligibility criteria for cases without any substantial loss of
heterogeneity (Table 1). This ability to stratify outcomes
by a number of clinically relevant variables will reduce
both structural and parameter assumptions when using
these data within economic models. Not only this, but also
our analysis, has shown that the heterogeneity of patients
within the specific community where the intervention is
implemented can be defined. This will be of increasing
value given the current interest in stratified or personalised
medicine and the need to find those people for whom
interventions are most cost effective [42, 43].
When we downloaded the CPRD and HES-linked
datasets for this study, we had data available in all
healthcare domains for at least 8 years. These datasets now
have at least 10 years of data for all domains and up to
30 years in primary care and prescriptions. This allows
follow-up of patients for much greater durations than
Table 2 Adjusted rate ratios for overall healthcare utilisation according to patient demographics
Variables Rate ratios (95 % CI)
Primary care
attendances
Prescriptions Outpatient appointments Inpatient and day-case
admissions
Colonoscopy
Sex
Male – – – – –
Female 1.26 1.35 1.21 1.03 0.80
(1.24–1.27) (1.32–1.37) (1.18–1.24) (0.95–1.11) (0.60–1.07)
Age at referral, years
18–29 – – – – –
30–49 1.06 (1.03–1.080 1.13 (1.10–1.17) 1.29 (1.23–1.36) 0.93 (0.83–1.04) 1.27 (0.71–2.27)
50–75 1.24 (1.21–1.27) 1.86 (1.80–1.92) 1.40 (1.33–1.46) 1.04 (0.93–1.16) 1.54 (0.87–2.76)
Duration of IBS before gastroenterology
appointment, years
Diagnosed at or following GI
visit
– – – – –
\1 1.02 (0.99–1.05) 1.03 (1.00–1.07) 1.05 (0.97–1.11) 1.00 (0.91–1.15) 0.99 (0.48–2.12)
1–2 1.05 (1.02–1.09) 1.01 (0.96–1.05) 0.99 (0.94–1.05) 1.14 (0.99–1.31) 1.12 (0.60–2.06)
2–5 1.20 (1.17–1.22) 1.34 (1.30–1.38) 1.22 (1.18–1.27) 1.12 (1.01–1.24) 1.14 (0.71–1.82)
5–10 1.09 (1.07–1.11) 1.15 (1.12–1.18) 1.10 (1.06–1.14) 0.96 (0.86–1.06) 0.81 (0.51–1.28)
[10 1.15 (1.14–1.18) 1.28 (1.25–1.31) 1.19 (1.15–1.23) 1.39 (1.25–1.54) 0.96 (0.66–1.40)
Socioeconomic status
Quintile 1 (highest) – – – – –
Quintile 2 1.13 (1.11–1.14) 1.08 (1.06–1.11) 1.09 (1.05–1.12) 1.04 (0.94–1.15) 1.86 (1.27–2.73)
Quintile 3 1.09 (1.07–1.10) 1.22 (1.19–1.25) 1.06 (1.02–1.09) 1.13 (1.02–1.25) 1.84 (1.23–2.76)
Quintile 4 1.17 (1.15–1.19) 1.20 (1.17–1.23) 1.23 (1.19–1.27) 1.23 (1.11–1.36) 0.98 (0.59–1.61)
Quintile 5 (lowest) 1.19 (1.16–1.21) 1.42 (1.39–1.46) 1.20 (1.63–1.25) 1.34 (1.19–1.47) 1.40 (0.88–2.24)
Smoking
Nonsmoker – – – – –
Smoker 1.19 (1.18–1.21) 1.40 (1.37–1.46) 1.07 (1.05–1.10) 1.13 (1.05–1.22) 0.57 (0.39–0.82)
Comorbidity
Score of 0 on Charlson index – – – – –
Score of 1 or greater on
Charlson index
1.19 (1.18–1.21) 1.22 (1.20–1.24) 1.23 (1.20–1.26) 1.18 (1.10–1.27) 0.87 (0.63–1.19)
Statistically significant ratios with a p value\0.05 are shown in bold
CI confidence interval, IBS irritable bowel syndrome, GI gastrointestinal
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usually possible with randomised controlled trials (RCTs).
Even though patients move between primary care practices,
on registering with a CPRD-linked practice all their sig-
nificant previous diagnoses are loaded into the CPRD
record. The HES data are lifelong. The duration of these
records is also therefore greater than in insurance datasets.
Alongside this, although not accessed for this study, death
registry data are linked to CPRD records. The duration of
follow-up reduces the need for extensive assumptions and
predictions regarding long-term outcomes, which can
reduce transparency and increase uncertainty and bias [44,
45].
The data within these datasets are generated through rou-
tine care. They reflect actual clinical practice rather than the
closely controlled setting of RCTs. RCTs can be highly
selected, with outcomes that are not replicated in general
clinical practice [46]. For economic evaluation, this means
that predictions and expectations based on such data are not
realised [47]. The real-world nature of the data in the CPRD
and HES means the outcomes are readily generalisable. These
databases are also more generalisable to the whole population
than results of similar studies from insurance claims data. The
NHS provides universal healthcare, unlike insurance compa-
nies. Datasets from these organisations are limited to people
eligible for public insurance or individuals insured by one
provider, and the terms of their insurance cover, for instance
which facilities they can access and when, may cause patients
to change their healthcare utilisation behaviour.
CPRD and HES data are relatively easily available on
application to the administrators; the cost data are all pub-
licly available. The nature of these data and the potential to
directly link costs to them make studies relatively cheap and
quick to replicate. Thus, policy outcomes can be efficiently
analysed as well as the predictions of cost-effectiveness
analyses in the postmarketing of drugs and devices.
4.3 Weaknesses of These Linked Datasets
One of the greatest weaknesses of using routinely collected
data is missing data. The CPRD is audited on a regular
Table 3 Annual rates of healthcare utilisation per person per year for 3 years before and after the first gastroenterology appointment
Healthcare domain Time from first gastroenterology outpatient appointment
3 years before 2 years before 1 year before 1 year after 2 years after 3 years after
Primary care attendances
Rate per person per
year (95 % CI)
8.1 (8.0–8.3) 8.4 (8.3 to 8.6) 10.7 (10.5–10.8) 9.7 (9.6–9.9) 9.1 (8.9–9.2) 9.7 (9.6–9.9)
Absolute difference in
attendances (95 % CI)
Baseline 0.3 (0.1 to 0.5) 2.6 (2.4–2.8) 1.6 (1.4–1.8) 1.0 (0.8–1.2) 1.6 (1.4–1.8)
Prescriptions
Rate per person per
year (95 % CI)
26.2
(24.7–27.7)
29.3 (27.6 to 31.1) 31.9 (30.0–33.8) 35.9 (33.8–38.0) 38.3 (36.1–40.6) 40.7 (38.3–43.1)
Absolute difference in
prescriptions (95 % CI)
Baseline 3.1 (2.8 to 3.4) 5.7 (5.4–6.0) 9.7 (9.4–10.0) 12.1 (11.8–12.5) 14.5 (14.1–14.9)
Outpatient appointments
Rate per person per
year (95 % CI)
1.9 (1.7–2.0) 2.1 (2.0 to 2.3) 2.6 (2.4–2.8) 3.9 (3.7–4.2) 3.4 (3.2–3.6) 3.4 (3.1–3.6)
Absolute difference in
attendances (95 % CI)
Baseline 0.2 (0.1 to 0.3) 0.7 (0.6–0.8) 2.0 (1.9–2.1) 1.5 (1.4–1.6) 1.5 (1.4–1.6)
Hospital admissions per
10 people per year
Rate per person per
year (95 % CI)
3.4 (2.9–3.9) 3.5 (3.1 to 4.0) 6.2 (5.6–6.8) 7.8 (7.2–8.4) 4.9 (4.3–5.5) 3.9 (3.4–4.5)
Absolute difference in
admissions (95 % CI)
Baseline 0.1 (-0.2 to 0.5) 2.8 (2.4–3.2) 4.4 (3.9–4.9) 1.5 (1.1–1.9) 0.5 (0.1–0.9)
Colonoscopies per
10 people per year
Rate per person per
year (95 % CI)
0.1a (0.1–0.2) 0.2 (0.2 to 0.3) 0.7 (0.6–0.8) 1.9 (1.7–2.1) 0.3 (0.2–0.3) 0.3 (0.2–0.4)
Absolute difference in
colonoscopies (95 % CI)
Baseline 0.1 (0.0 to 0.2) 0.6 (0.5–0.7) 1.8 (1.6–2.0) 0.2 (0.1–0.3) 0.2 (0.1–0.3)
IBS irritable bowel syndrome, CI confidence interval
a Rate of 0.1 colonoscopies/10 people/year = 1 in 100 IBS patients having a colonoscopy in that year
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basis to ensure that the data recorded are complete and
accurate [4, 18]. Despite this, in fewer than 5 % of records
event dates are not recorded or diagnostic codes are
missing. This was higher in the HES outpatient data
(12 %). The missingness of these data is likely to be ran-
dom. Consequently, in this study we had sufficient data to
exclude those records. Other data are not recorded at all.
One example from this study was disease severity. For
other conditions, diagnostic codes or other recorded
information such as investigation results indicate disease
severity, but for IBS there are no such data. Similarly,
within these datasets no data record symptom improvement
or quality-of-life information. This means that for diseases
such as IBS with no attributable mortality or pathophysi-
ological measurement, deterioration or improvement is
unknown. This makes deriving disease-state transition
probabilities very difficult in conditions such as IBS. In
other conditions with clearly demarcated disease states, the
proportion of a cohort in each state over time would be
easier to define.
A limitation of any electronic database study within
healthcare is the difficulty in verifying coding accuracy.
CPRD data are regularly audited to ensure their quality
[18]. Many studies have assessed the internal validity of
CPRD coding, using either algorithms or sensitivity anal-
yses, and the external validity by directly reviewing patient
records or sending general practitioners questionnaires [48,
49]. Over a range of 183 diagnoses, the median proportion
of cases confirmed was 89 % [48]. Coding for IBS
specifically has been validated via questionnaires to gen-
eral practitioners, who confirmed IBS diagnosis in 99 % of
patients with a first IBS code whilst enrolled at that prac-
tice, and 84 % of patients with an IBS code from a pre-
vious practice [50]. Individual coding errors are likely to be
independent of any intervention or population analysed,
and independent of cost. Consequently, it is unlikely that
differential misclassification from inaccurate coding occurs
at an individual level. However, it is likely that changes in
external factors that link recorded outcomes to reimburse-
ment change the accuracy and frequency of coding, which
could introduce bias [51, 52].
Within these datasets, the duration of patient enrolment
varies. We had sufficient cases to restrict our analysis to
only those patients with 3 full years of data either side of
the first gastroenterology appointment. Limiting our pop-
ulation could introduce selection bias towards relatively
well patients and those less likely to move, such as older
patients. This would not be an appropriate approach if the
condition under investigation had associated mortality
impact, but IBS does not. Comparing all eligible patients
with gastroenterology appointments in 2008 or 2009 with
those who had data available for the full 6 years (Table 1),
the demographics remain broadly similar. There isT
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Calculating Total Health Service Utilisation and Costs
evidence of proportionally fewer patients aged under
30 years being eligible but this has little effect on the mean
age of the sample. In situations where survival (or mor-
tality) was important, or selecting only patients with
complete years of data would cause substantial selection
bias, inverse probability weighting of costs would be an
appropriate method for analysis [53].
The nature of the CPRD and HES datasets mean that the
utilisation data and associated costs are from the payer’s
perspective only. In the current climate, this is adequate for
Health Technology Assessments. If conducting an analysis
of societal impact, then additional data from other sources
would be required. Likewise, these data are UK-specific,
which might limit generalisability outside the NHS. For
similarly organised healthcare systems, it is feasible to
attach other system-specific costing structures to the utili-
sation data but this would need further analysis.
A gastroenterology appointment for IBS diagnosis or
management is not currently recommended as best practice
[9, 12] therefore referral from primary care is not stan-
dardised. Consequently, the patients who see a gastroen-
terologist are likely to be systematically different to those
who do not. It is for this reason that we used a before and
after study design. However, these data cannot establish the
counterfactual utilisation and cost trajectories in the
absence of a gastroenterology appointment. For instance, it
is possible that utilisation and costs increase in these
patients if they do not visit a gastroenterologist. Comparing
these patients with IBS to those never referred would lead
to confounding by indication. This is a limitation of the
data in these databases compared with RCT data. Propen-
sity score matching has gained popularity for assessing the
probability of intervention allocation according to baseline
covariates [54]. This method relies on known and measured
variables, at least partially explaining differences between
those referred and not referred. Table 1 shows that the
demographic variables we measured were similar between
the referred and nonreferred patients, which makes
propensity score matching less useful here. It has previ-
ously been found that the factors most likely to predict
referral to a gastroenterologist are reporting stress wors-
ening symptoms and having more than three bowel
movements per day, which are not variables recorded
within the CPRD and HES dataset [13]. Alternatively,
epoch analysis aims to estimate causal effect when patients
switch interventions during longitudinal observational
studies [55]. However, in our study, referral to gastroen-
terology is a once-only intervention. Patients who are
‘never referred’ can become ‘referred’, but not vice versa.
Thus, to use these datasets to assess the potential cost
effectiveness of referring patients with IBS to gastroen-
terology, assumptions regarding utilisation and costs in the
absence of a gastroenterology referral should be included
in a scenario analysis. As these datasets develop, their
strengths in size and in reflecting actual clinical practice
can be maintained by conducting a randomised trial
prospectively through the CPRD general practices [56]. For
instance, it is now possible to alert CPRD-linked general
practitioners through their electronic records system when
they consult patients potentially eligible for a trial [56, 57].
Fig. 2 Total mean individual cost each year and the contribution of each component of care to the total
C. Canavan et al.
The lack of linked quality-of-life data within these
datasets means that linking the utilisation and cost out-
comes with other sources of quality-of-life data for a cost-
effectiveness study will be challenging. However, we
acknowledge that this would be less difficult in conditions
with well-defined disease progression indicators recorded
within routine healthcare data. We have demonstrated the
greatest strength in these data is the capacity to define
patient-level demographic factors, comorbidities and risk
factors, and link them with specific costs. The potential for
these data is substantial. Individual-level simulations using
these data could directly sample individuals, avoiding the
need to generate hypothetical ‘patients’ from parameter
distributions [58], and might provide better adjustment for
unknown confounders [59, 60]. There is also great interest
in the potential of real-world electronic health data for
validating economic model predictions [61]. The large
numbers of records available with data that allow charac-
terisation of patient heterogeneity will become more useful
with increasing stratification of patient’s treatment
according to risk factors or predictors of response.
5 Conclusions
These linked datasets provide useful data for large numbers
of patients, which allows stratification of costs and new
insights into healthcare utilisation. It is possible to derive
Table 5 Mean total and stratified costs in the 3 years before gastroenterology appointment
Variables 3 years before 2 years before Year before
Mean cost (£) Gamma distribution
parameters
Mean
cost (£)
Gamma distribution
parameters
Mean
cost (£)
Gamma distribution
parameters
a k (E-04) a k (E-04) a k (E-04)
Sex
Male 1817.85 0.521 2.86 1870.64 0.592 3.16 2470.63 0.549 2.22
Female 2498.56 0.604 2.42 2772.55 0.587 2.12 3319.43 0.675 2.03
Age at referral, years
18–29 1087.85 0.367 3.38 1199.16 0.397 3.31 1705.34 0.621 3.64
30–49 1689.19 0.434 2.57 1816.55 0.394 2.17 2375.27 0.398 1.67
50–75 2780.3 0.658 2.36 3081.77 0.675 2.19 3804.21 0.906 2.38
Duration of IBS before
gastroenterology
appointment, years
Diagnosed at GI visit 1838.44 0.404 2.20 2017.91 0.450 2.23 2576.35 0.448 1.74
B1 1477.07 0.448 3.03 1687.56 0.553 3.27 2525.64 0.485 1.92
[1–2 1865.15 0.658 3.53 2079.95 0.584 2.81 2565.72 0.651 2.54
[2–5 3084.4 0.579 1.88 3087.14 0.535 1.73 3707.28 0.736 1.99
[5–10 2320.97 0.567 2.44 2700.11 0.502 1.86 3123.86 0.659 2.11
[10 2761.26 0.826 2.99 2993.68 0.790 2.64 3518.98 0.817 2.32
Socioeconomic status
Quintile 1 1910.21 0.533 2.79 2140.47 0.616 2.88 2664.62 0.613 2.30
Quintile 2 2154.37 0.575 2.67 2386.59 0.521 2.18 2770.69 0.670 2.42
Quintile 3 2387.75 0.638 2.67 2579.91 0.673 2.61 3064.04 0.883 2.88
Quintile 4 2564.55 0.570 2.22 2780.61 0.586 2.11 3563.49 0.494 1.39
Quintile 5 3006.9 0.660 2.19 3220.69 0.549 1.71 3914.92 0.780 1.99
Smoking
Nonsmoker 2129.81 0.517 2.43 2316.08 0.471 2.03 2807.32 0.555 1.98
Smoker 2906.56 0.781 2.69 3214.22 0.963 3.00 3996.17 0.954 2.39
Comorbidity (according
to Charlson score)
Score of 0 2202.98 0.548 2.49 2399.62 0.511 2.13 2936.73 0.587 2.00
Score of 1 or greater 2666.33 0.660 2.48 2936.89 0.750 2.55 3558.36 0.795 2.23
All costs approximated a gamma distribution, therefore a (mean2/sd2) and k (mean/sd2) parameters are shown for each stratum
IBS irritable bowel syndrome, GI gastrointestinal
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relevant parameters and distributions directly from the
population of interest. We advise caution when choosing to
use these datasets, depending on the disease investigated, if
the aim is to use the outcomes generated in cost-effec-
tiveness analysis. The important disease states, or markers
of them, should be events routinely recorded in healthcare
data so states can be adequately characterised and linked to
quality-of-life data from other sources.
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Table 6 Mean total and stratified costs in the 3 years after gastroenterology appointment
Variables Year after 2 years after 3 years after
Mean cost (£) Gamma distribution
parameters
Mean
cost (£)
Gamma distribution
parameters
Mean
cost (£)
Gamma distribution
parameters
a k (E-04) a k (E-04) a k (E-04)
Sex
Male 2909.77 0.738 2.54 2926.05 0.540 1.85 2993.08 0.472 1.58
Female 3689.36 0.703 1.90 3664.94 0.599 1.63 3773.38 0.530 1.40
Age at referral, years
18–29 2202.99 0.629 2.86 1646.94 0.573 3.48 1494.98 0.503 3.37
30–49 2715.76 0.505 1.86 2719.02 0.393 1.44 2822.17 0.270 0.96
50–75 5733.74 1.859 3.24 4048.32 0.694 1.71 4162.51 0.725 1.74
Duration of IBS before
gastroenterology appointment, years
Diagnosed at GI visit 3238.05 0.627 1.93 3145.46 0.411 1.31 3298.31 0.241 0.73
\1 2937.96 0.672 2.29 2346.75 0.440 1.87 2504.39 0.516 2.06
1–2 3176.75 1.256 3.95 2364.43 0.720 3.04 2349.72 0.716 3.05
2–5 4502.85 0.901 2.00 4005.88 0.657 1.64 3844.45 0.617 1.60
5–10 3803.45 0.954 2.51 3517.31 0.724 2.06 3658.14 0.644 1.76
[10 4120.24 0.860 2.09 4072.91 0.706 1.73 4183.91 0.847 2.02
Socioeconomic status
Quintile 1 3219.41 0.892 2.77 3044.86 0.616 2.02 2367.6 0.390 1.65
Quintile 2 3482.04 0.670 1.92 3130.48 0.449 1.43 3152.92 0.670 2.13
Quintile 3 3785.39 0.909 2.40 3624.1 0.733 2.02 3801.64 0.406 1.07
Quintile 4 4223.21 0.690 1.63 3804.11 0.538 1.41 3976.08 0.486 1.22
Quintile 5 4377.85 1.482 3.39 4258.9 0.699 1.64 4583.85 0.582 1.27
Smoking
Nonsmoker 3414.48 0.726 2.13 3105.28 0.509 1.64 3132.32 0.534 1.71
Smoker 4681.73 1.082 2.31 4610.45 0.854 1.85 4918.38 0.565 1.15
Comorbidity (according
to Charlson score)
Score of 0 3492.88 0.746 2.14 3270.07 0.534 1.63 3319.78 0.539 1.62
Score of 1 or greater 4388.77 0.974 2.22 4062.4 0.728 1.79 4285.15 0.494 1.15
All costs approximated a gamma distribution, therefore a (mean2/sd2) and k (mean/sd2) parameters are shown for each stratum
IBS irritable bowel syndrome, GI gastrointestinal
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